Shaji Kumar on Later Lines of Treatment for Myeloma
There are several agents available for patients who experience recurrence, Kumar says, though nearly all of them have the potential to move to an earlier setting.
BY Shaji Kumar
PUBLISHED September 22, 2015
Shaji Kumar, professor of medicine, Division of Hematology, Mayo Clinic, provides an overview of later lines of therapy for patients with multiple myeloma.
There are several agents available for patients who experience recurrence, Kumar says, though nearly all of them have the potential to move to an earlier setting.